

Haematologica  
HAEMATOL/2017/168740  
Version 3

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy

Simone Claudiani, Jane Apperley, Robert Peter Gale, Richard Clark, Richard Szydlo, Simona Deplano, Renuka Palanicawandar, Jamshid Khorashad, Letizia Foroni, and Dragana Milojkovic

Disclosures: Simone Claudiani: none. Jane Apperley: research grants from Novartis, Ariad and Pfizer. Robert Gale is part time employee of Celgene Corporation. Richard Clark: honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad; advisory board with Novartis, Bristol-Myers Squibb, Pfizer; research funding from Novartis, Pfizer and Bristol-Myers Squibb. Richard Szydlo: none. Simona Deplano: none. Renuka Palanicawandar: none. Jamshid Khorashad: none. Letizia Foroni: research grants from Novartis. Dragana Milojkovic: honoraria from Novartis, Ariad, Pfizer and Bristol-Myers Squibb.

Contributions: S.C. designed research, collected data, analysed and interpreted data and wrote the manuscript; J.A. and RG: interpreted data and reviewed the manuscript; R.C. collected data and reviewed the manuscript; R.S., S.D., R.P., J.K., L.F. and D.M. reviewed the manuscript.